PHE575 / PharmaEssentia - LARVOL DELTA

Novel NLRP3 inhibitors mitigate acute radiation-induced lung injury by suppressing pyroptosis in alveolar epithelial cells. (PubMed, Toxicol Appl Pharmacol) - "The NLRP3 inhibitors QK-3D and QK-3E effectively alleviate RILI by suppressing AT2 pyroptosis via NLRP3/GSDMD pathway inhibition, offering a potent and safe therapeutic candidate for early intervention. This study advances pyroptosis-targeted strategies for inflammatory diseases."

Journal • Cardiovascular • Oncology • Respiratory Diseases • Thoracic Cancer • GSDMD • IL18 • IL1B • NLRP3

Computational Exploration of Phenolic Compounds from Endophytic Fungi as α-Glucosidase Inhibitors for Diabetes Management. (PubMed, ACS Omega) - "BUT interacted specifically with both key residues, Asp443 and Phe575, critical for enzyme-inhibitor stability...These findings suggest that PCs possessing butenolide scaffolds, like BUT and ALD, hold great promise as potential AGIs for managing T2D. These findings, however, need to be further validated through in vivo experimentation."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • MGAM

Molecular Docking and Dynamics Simulations Studies of a Dataset of NLRP3 Inflammasome Inhibitors. (PubMed, Recent Adv Inflamm Allergy Drug Discov) - "This report confirmed the stability of NP3-146, similar to the know inhibitor MCC950, and provides various information useful to design NLRP3 inhibitors."

Journal • CNS Disorders • Diabetes • Immunology • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • NLRC5 • NLRP3